Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052828 | 0.87 | RAB9A (0.37) | LOXL2KDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL12052800 | 0.78 | LMNA (0.36) | ACACBTRPA1 | |
| SCHEMBL12050858 | 0.77 | TDP1 (0.38) | ACACBNAMPTKDM4EALDH1A1MAPT | |
| SCHEMBL12052797 | 0.76 | PTPRC (0.40) | TRPA1LOXL2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12050836 | 0.75 | CA1 (0.37) | TRPA1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12052799 | 0.73 | TRPA1 (0.40) | TRPA1LOXL2KDM4EALDH1A1MAPT | |
| SCHEMBL12052798 | 0.72 | TRPA1 (0.39) | TRPA1LOXL2KDM4EALDH1A1MAPT | |
| SCHEMBL12052803 | 0.70 | LOXL2 (0.36) | TRPA1LOXL2KDM4EALDH1A1MAPT | |
| SCHEMBL12050837 | 0.70 | MAPK14 (0.44) | LOXL2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12050838 | 0.69 | LOXL2 (0.40) | ACACBTRPA1LOXL2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | ACACB 746/4885TRPA1 3541/4885NAMPT 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.